NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.

Trial Details

NCT ID
NCT05773859
Phase
PHASE1 / PHASE2
Sponsor
Radboud University Medical Center
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • XP-DC vaccinations
Locations (sample)
  • Nijmegen, Gelderland, Netherlands|51.8425,5.85278

Key Eligibility Criteria

  • Women over 18 years old with histologically confirmed primary epithelial ovarian cancer.
  • Not amenable by primary debulking surgery and in need of neoadjuvant chemotherapy and interval debulking
  • High-grade or low grade serous histology
  • FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes ≤ 1cm above the diaphragm or in the groins

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →